间变性淋巴瘤激酶
癌症研究
癌变
间变性大细胞淋巴瘤
淋巴瘤
突变
生物
医学
癌症
遗传学
肿瘤科
基因
免疫学
肺癌
恶性胸腔积液
作者
Felipe Pantoja Mesquita,Luína Benevides Lima,Emerson Lucena da Silva,Pedro Filho Noronha Souza,Maria Elisabete Amaral de Moraes,Rommel Rodrı́guez Burbano,Raquel Carvalho Montenegro
出处
期刊:Current Protein & Peptide Science
[Bentham Science]
日期:2024-02-28
卷期号:25
标识
DOI:10.2174/0113892037291318240130103348
摘要
Abstract: Gastric adenocarcinoma is a complex disease with diverse genetic modifications, including Anaplastic Lymphoma Kinase (ALK) gene changes. The ALK gene is located on chromosome 2p23 and encodes a receptor tyrosine kinase that plays a crucial role in embryonic development and cellular differentiation. ALK alterations can result from gene fusion, mutation, amplification, or overexpression in gastric adenocarcinoma. Fusion occurs when the ALK gene fuses with another gene, resulting in a chimeric protein with constitutive kinase activity and promoting oncogenesis. ALK mutations are less common but can also result in the activation of ALK signaling pathways. Targeted therapies for ALK variations in gastric adenocarcinoma have been developed, including ALK inhibitors that have shown promising results in pre-clinical studies. Future studies are needed to elucidate the ALK role in gastric cancer and to identify predictive biomarkers to improve patient selection for targeted therapy. Overall, ALK alterations are a relevant biomarker for gastric adenocarcinoma treatment and targeted therapies for ALK may improve patients' overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI